NEW CANAAN, CT--(Marketwire - December 01, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has filed an application with the United States Food and Drug Administration for an Investigative New Drug (IND) approval to undertake clinical studies with triphendiol as a chemosensitizing agent in combination with gemcitabine. The IND application is to enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers.
